Clinical Trial Update: Empagliflozin in ESKD - A Feasibility Study [Phase 1, Phase 2]

View source ↗

Summary

A feasibility study of empagliflozin in end-stage renal disease with heart failure is ongoing across Phase 1 and Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Heart Failure

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University of Mississippi Medical Center | Conditions: Kidney Failure, Chronic, Heart Failure | Phase 1, Phase 2 | Status: RECRUITING